1. Celli BR, MacNee W and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper//Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–46.
2. Лещенко И.В. Глобальная инициатива при хронической обструктивной болезни легких 2006: значение длительно действующих бронходилататоров. Consilium Medicum 2007; 9 (10): 10–3.
3. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004; 3: CD003794.
4. Aaron SD, Vandemheen K, Fergusson D et al. The Canadian Optimal Therapy of COPD Trial: Design, organization and patient recruitment. Can Respir J 2004; 11 (8): 581–5.
5. Miravitlles M. New treatments for chronic obstructive pulmonary disease. Med Clin (Barc) 2005; 125 (2): 65–74.
6. Авдеев С.Н. Возможна ли модификация заболеваний при хронической обструктивной болезни легких? Роль бронходилататора длительного действия тиотропия бромида. Consilium Medicum 2008; 10 (3): 57–64.
7. Овчаренко С.И., Голиковой Е.П. Спирива – эффективный препарат, уменьшающий одышку и частоту обострений при хронической обструктивной болезни легких (данные клинических испытаний). Пульмонология. 2003; 6: 103–7.
8. Anzueto A. Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions. Am J Med 2006; 119 (10 Suppl. 1): 46–53.
9. O'Connor BJ, Towse L., Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996; 154 (4, Pt 1): 876–80.
10. Littner MR, Ilowite JS, Tashkin DP et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161 (4, Pt 1): 1136–42.
11. Casaburi R, Briggs DDJr, Donohue JF et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000; 118 (5): 1294–302.
12. van Noord JA, Bantje TA, Eland ME et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55 (4): 289–94.
13. Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs 2001; 10 (4): 733–40.
14. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19 (2): 217–24.
15. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124 (5): 1743–8.
16. McNicholas WT, Calverley PM, Lee A, Edwards JC. Tiotropium Sleep Study in COPD Investigators: Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004; 23 (6): 825–31.
17. Визель А.А., Пронина Е.Ю., Сергеев В.А. и др. Тиотропия бромид в комплексной терапии больных с ХОБЛ: оценка эффекта первой упаковки. Клин. фармакол. и тер. 2005; 4: Прил.. Тезисы I конференции «Качественное использование лекарств и фармаконадзор», Казань: 162–3.
18. Niewoehner DE, Rice K, Cote C et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143 (5): 317–26.
19. Friedman M, Menjoge SS, Anton SF, Kesten S. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with Chronic Obstructive Pulmonary Disorder (COPD). Pharmacoeconomics 2004; 22 (11): 741–9.
20. Laforest L, Ritleng C, Van Ganse E. Dispensing patterns of tiotropium at initiation in patients from the rhone-alpes region: results from an observational survey. Eur Resp J 2009; 34 (Suppl. 53): Ref. E1451.
21. Somand H, Remington TL. Tiotropium: A bronchodilator for Chronic Obstructive Pulmonary Disease. Ann Pharmacother 2005; 39 (9): 1467–75.
22. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 2: CD002876.
23. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006; 27 (3): 547–55.
24. Anzueto A. Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions. Am J Med 2006; 119 (10 Suppl. 1): 46–53.
25. van Noord JA, Cornelissen PJ, Aumann JL et al. The efficacy of tiotropium administered via Respimat(R) Soft Misttrade mark Inhaler or HandiHaler(R) in COPD patients. Respir Med 2009; 103 (1): 22–9.
26. Decramer M, Celli B, Kesten S, Lystig T et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet 2009 Aug 27. Epub ahead of print.
27. Celli B, Decramer M, Kesten S et al. Mortality in the 4 Year Trial of Tiotropium (UPLIFT) in Patients with COPD. Am J Respir Crit Care Med 2009; Sep 3. Epub ahead of print.
28. Tashkin DP, Celli B, Kesten S et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2009; Aug 28. Epub ahead of print.
29. Celli B, Kesten S, Lystig T et al.COPD patients under 50 years of age: 4-year follow-up in the UPLIFT trial. Europ Resp J 2009; 34 (Suppl. 53): Ref. P3801.
30. Troosters T, Celli D, Kesten S et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the uplift trial. Eur Resp J 2009; 34 (Suppl. 53): Ref. P3808.
31. Hanania N, Kesten S, Celli B et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium. Eur Resp J 2009; 34 (Suppl. 53): Ref. E4353.
32. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123 (5): 1441–9.
33. Myronenko O. Respiratory muscles' function in chronic obstructive pulmonary disease patients treted with anticholinergic bronchodilator. Eur Resp J 2009; 34 (Suppl. 53): Ref. P3508.
34. Yoshimura K, Hiraga T, Kitada S et al. Effects of tiotropium on neurohumoral activation during exercise in stable COPD patients. Eur Resp J 2009; 34 (Suppl. 53): Ref. E4364.
35. Hasani A, Toms N, Agnew JE et al. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004; 125 (5): 1726–34.
36. Pertseva T, Lykholat O, Gurzhiy O. Influence of tiotropium bromide (TB) on mucociliary clearance (MCC) in patients with COPD. Eur Resp J 2009; 34 (Suppl. 53): Ref. P3458.
37. Dicpinigaitis PV, Spinner L, Santhyadka G, Negassa A. Effect of Tiotropium on cough reflex sensitivity in acute viral cough lung. 2008; 186 (6): 369–74.
38. Saito Y, Azuma A, Morimoto T et al. Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to macrolide therapy. Intern Med 2008; 47 (7): 585–91.
39. Bu..hling F, Lieder N, Ku..hlmann UC et al. Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro. Respir Med 2007; 101 (11): 2386–94.
40. Pieper MP, Chaudhary NI, Park JE. Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide. Life Sci 2007; 80 (24–25): 2270–3.
41. Shikama Y, Asano K, Shibuya Y et al. Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro. Eur Resp J 2009; 34 (Suppl. 53): Ref. P4668.
42. Wollin L, Pieper M. Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD. Eur Resp J 2009; 34 (Suppl. 53): Ref. P2004.
43. Ishii Y, Fujimoto S, Baba C, Fukuda T. Tiotropium inhalation prevents acute cigarette smoke-induced airway inflammation in mice. Eur Resp J 2009; 34 (Suppl. 53): Ref. P937.
44. Zaagsma J, Pera T, Zuidhof AB et al. Remoddeling and inflammation in a guinea pig model of COPD: effects of tiotropium. Eur Resp J 2009; 34 (Suppl. 53): Ref. E2944.
45. Shibuya Y, Shikama Y, Asano K et al. Attenuating effect of tiotropium bromide on IL-8 production from human bronchial epithelial cells, BEAS-2B in vitro. Eur Resp J 2009; 34 (Suppl. 53): Ref. P863].
46. Profita M, Riccobono L, Montalbano AM et al. Non-neuronal components of cholinergic system in peripheral blood T-cells of COPD patients. Eur Resp J 2009; 34 (Suppl. 53): Ref. P915.
47. ZuWallack AR, ZuWallack RL. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease. Exp Opin Pharmacother 2004; 5 (8): 1827–35.
48. Matera MG, Sanduzzi A, Ponticiello A et al. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses. Respiration 2005; 72 (5): 466–70.
49. Salvi S, Bhosle K, Brashier B et al. Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma. Eur Resp J 2009; 34 (Suppl. 53): Ref. E276.
50. Baloira Villar A, Vilarino Pombo C. Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease. Arch Bronconeumol 2005; 41 (3): 130–4.
51. Bateman ED, van Dyk M, Sagriotis A. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: A pilot study. Pulm Pharmacol Ther 2008; 21 (1): 20–5.
52. Aaron SD, Vandemheen K, Fergusson D et al. The Canadian Optimal Therapy of COPD Trial: Design, organization and patient recruitment. Can Respir J 2004; 11 (8): 581–5.
53. Wedzicha JA, Calverley PM, Seemungal TA et al. INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177 (1): 19–26.
54. Aaron SD, Vandemheen KL, Fergusson D et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146 (8): 545–55.
55. Biscione G, Crigna G, Auciello L et al. Addition of tiotropium (T) to a regular treatment with long-acting beta-agonist+inhaled corticosteroid (LABA+ICS) in patients with severe to very-severe COPD under in-patient pulmonary rehabilitation program (PRP). Eur Resp J 2009; 34 (Suppl. 53): Ref. P526.
56. Cazzola M, Marco FD, Santus P et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17 (1): 35–9.
57. van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26 (2): 214–22.
58. Terzano C, Petroianni A. Rational timing of combination therapy with tiotropium and formoterol in moderate-severe COPD. Eur Resp J 2006; 28 (Suppl. 50): Ref. P1272.
59. Vogelmeier C, Kardos P, Harari S et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study. Respir Med 2008; 102 (11): 1511–20.
60. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD Chest 134 (2): 255–62.
61. Welte T, Miravitlles M, Hernandez P et al. Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms & morning activities in COPD patients. Eur Resp J 2009; 34 (Suppl. 53): Ref. P2005.
62. Welte T, Miravitlles M, Hernandez P et al. Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD. Europ Resp J 2009; 34 (Suppl. 53): Ref. P2012.

А.А.Визель, И.Ю.Визель